Jennifer Ng
Lawyers
Advises issuers and investment banks on a broad spectrum of transactions, including Hong Kong IPOs, offerings and placings, as well as corporate governance matters.
Jennifer has extensive experience in representing leading companies and investment banks on capital markets transactions, particularly in Hong Kong IPOs and listings. She has advised clients on a number of high-profile HKEX IPOs across various sectors, including technology, healthcare and consumer products. Jennifer also advises HKEX-listed companies on compliance, major corporate transactions (including public takeovers) and corporate governance.
Experience highlights
Recent Representations
- HighTide Therapeutics HK$194.1 million IPO
- Zhejiang Expressway $860 million rights issue
- Keep HK$313 million IPO
- Cutia Therapeutics HK$412.9 million IPO
- Beisen Holding HK$155 million IPO
- Kingsoft Cloud dual primary listing on the Hong Kong Stock Exchange
- Tencent Music Entertainment Group secondary listing
- Biocytogen HK$549 million IPO
- Taibang Biologic Group $300 million equity raising
- Beike’s dual primary listing on the Hong Kong Stock Exchange
- CNOOC RMB28 billion Shanghai IPO
- CANbridge Pharmaceuticals HK$685 million IPO
- ANE HK$1.1 billion IPO
Credentials
Recognition
IFLR1000 – Equity Capital Markets, M&A, Hong Kong
ALB Hong Kong Law Awards – “Young Lawyer of the Year,” 2019
Education
PCLL, University of Hong Kong, Faculty of Law
LL.B., University of Hong Kong, Faculty of Law
B.B.A., University of Hong Kong
Professional history
- Counsel, 2023-present
- Davis Polk since 2021
Qualifications and admissions
- Hong Kong